title: CA 72-4 levels in patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  CA 72-4 is one of the blood group carbohydrate antigens which can be used as a tumour marker in ovarian, pancreatic and gastrointestinal carcinomas. It can also be elevated in various benign conditions including pancreatitis. Diabetes mellitus is a chronic disorder related with the pancreas. In this study, we investigated CA 72-4 levels in patients with type 2 diabetes and its relation to the metabolic status.
  
  
  METHODS
  Sixty-nine patients with type 2 diabetes mellitus (female/male = 40/29) and 60 healthy subjects (female/male = 35/25) participated in this study. The levels of serum CA 72-4 were measured and faecal occult blood tests (following 3 days of white diet were obtained for three consecutive days) were performed in all patients. Patients had a pathological finding for any of these two parameters were further investigated with upper gastrointestinal endoscopy, colonoscopy and computerised tomography.
  
  
  RESULTS
  The mean levels of CA 72-4 was 1.89 +/- 2.61 U/ml in the study group and 1.4 +/- 0.98 U/ml in the control group (p > 0.05). There was no association between CA 72-4 levels and age and sex of the patients, duration of diabetes, body mass index, biochemical indicators of metabolic control (the levels of HbA(1c), fasting and postprandial glucose, serum lipids), the presence of microvascular complications (retinopathy, nephropathy, neuropathy) or treatment modalities.
  
  
  CONCLUSIONS
  Elevated levels of CA 72-4 in diabetic patients are not related to diabetes and it should be interpreted as evaluated in a non-diabetic patient.
authors.affiliation: Department of Endocrinology, Gazi University Faculty of Medicine, Ankara, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Demirci
authors.forename: H
authors.initials: H
authors.lastname: Erdamar
authors.forename: A
authors.initials: A
authors.lastname: Karakoc
authors.forename: M
authors.initials: M
authors.lastname: Akturk
authors.forename: M
authors.initials: M
authors.lastname: Yilmaz
authors.forename: M
authors.initials: M
authors.lastname: Arslan
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000378:metabolism*; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy / Q000276:immunology*; D003925:Diabetic Angiopathies / Q000178:diet therapy / Q000188:drug therapy / Q000276:immunology*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D009780:Occult Blood
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; C083825:CA-72-4 antigen